Heranova Lifesciences Debuts with $13.5 Million Seed and Seed+ Round Funding to Offer Integrated Clinical Solutions to Women's Health

December 29, 2023 12:00 AM AEDT | By Cision

Google News:

Heranova Lifesciences Debuts with $13.5 Million Seed and Seed+ Round Funding to Offer Integrated Clinical Solutions to Women's Health — Image source: Kalkine Media

Recent News

Canada job gains mask weakness, Macquarie says

Stop Buying Energy Infrastructure. Start Buying Results.

As dollar eyes third-weekly win, traders are doubling down on their be...

How a Marathon Petroleum Grant Empowered a Future Teacher of the Year

BOSTON and HONG KONG, Dec. 28, 2023 /PRNewswire/ -- Heranova Lifesciences Holding Ltd. ("Heranova") today announced the successful completion of a USD 13.5 million seed and seed+ financing to develop and offer integrated Women's Health solutions worldwide. This funding will be used to launch a serial of non-invasive endometriosis tests and advance two innovative (non-hormonal and non-antibiotic) therapeutic programs for endometriosis and bacterial vaginosis. The company is also actively seeking global or regional partnerships for other Women's Health indications. Institutional investors such as Pivotal bioVenture Partners China, Sinovation Ventures, Emerging Technology Partners, and Triwise Capital participated in this round.

"Despite the fact that women play a critical role in modern societies and economy, the awareness and solutions for their critical health issues are largely under-recognized and outdated," said Dr. Jonathan Y. Zhao, co-founder and CEO of Heranova. "As a global Women's Health company, Heranova was founded with a mission to challenge this status quo by taking a holistic approach so that we could enable women to live their better lives."

"Endometriosis, for example, is a highly prevalent and debilitating women's disease with large diagnostic and treatment unmet needs. 176 million endometriosis patients worldwide are suffering from excessive pain, abnormal menstrual bleeding, and infertility," said Dr. Hugh Taylor, Chief of Obstetrics and Gynecology at Yale New Haven Hospital, and member of Heranova's Scientific Advisory Board. "Unfortunately, the diagnosis of endometriosis today is often delayed by 8-12 years on average. We are excited to see that Heranova is committed to bringing innovative solutions to address this care gap."

"Having access to convenient and reliable diagnostic tests will be a key milestone in the overall management of endometriosis and other women's diseases," said Dr. Farideh Bischoff, the Chief Diagnostic Medical Officer at Heranova. "The diagnostic products developed by our R&D team have received endorsement from global leading KOLs as they may help to significantly shorten the time from disease onset to diagnosis and subsequent treatment. To provide an integrated solution, we are also developing first-in-class, non-hormonal therapeutic programs for endometriosis."

About Heranova Lifesciences

Heranova Lifesciences is a Boston-based biotech company solely focused on developing integrated care solutions for Women's Health. Their goal is to address unmet needs in women's healthcare by offering internally developed and externally partnered diagnostics, drugs, and devices. The company was founded in 2022 by a team of serial entrepreneurs and seasoned MNC executives with support from a world-class Scientific Advisory Board. Heranova has already established presences in the United States and Asia.

To learn more about Heranova please visit www.heranovalifesciences.com.

CONTACT: Yikai Xu, yikai.xu@heranovalifesciences.com

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.